Evidence map›Paper›PMID 38692663›Full record

ArticleInfluenza and other respiratory viruses2024

Assessment of Illness Severity in Adults Hospitalized With Acute Respiratory Tract Infection due to Influenza, Respiratory Syncytial Virus, or Human Metapneumovirus.

Ann R Falsey, Edward E Walsh, Stacey L House, Yannick Vandendijck, Marita Stevens, Eric K H Chan, Gabriela Ispas

Open access · goldAbstract read
In one paragraph

Article in Influenza and other respiratory viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Observational
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Ann R FalseyDepartment of Medicine, University of Rochester, Rochester, New York, USA.ORCID 0000-0002-7141-9701
Edward E WalshDepartment of Medicine, University of Rochester, Rochester, New York, USA.
Stacey L HouseDepartment of Emergency Medicine, School of Medicine, Washington University, St. Louis, Missouri, USA.
Yannick VandendijckJanssen Research & Development, Beerse, Belgium.ORCID 0000-0002-3117-317X
Marita StevensJanssen Research & Development, Beerse, Belgium.ORCID 0000-0001-5233-8917
Eric K H ChanJanssen Global Services, LLC, Raritan, New Jersey, USA.
Gabriela IspasJanssen Global Medical Affairs Infectious Diseases & Vaccines, Beerse, Belgium.
Janssen (Belgium) · BEUniversity of Rochester · USJanssen (United States) · USWashington University in St. Louis · US

Funding

Janssen Pharmaceuticals
6 · The paper itself

Abstract

backgroundInfluenza, respiratory syncytial virus (RSV), and human metapneumovirus (hMPV) are common respiratory viruses causing similar symptoms. Optimal tools to assess illness severity for these viruses have not been defined. Using the Hospitalized Acute Respiratory Tract Infection (HARTI) study data, we report symptom severity by clinician-rated clinical severity scores (CSS) in adults with influenza, RSV, or hMPV and correlations between CSS and patient-reported outcomes (PROs).

methodsHARTI was a global epidemiologic study in adults hospitalized with acute respiratory tract infections. Patients were assessed at enrollment within 24 h of admission with CSS and twice during hospitalization with CSS, Respiratory Infection Intensity and Impact Questionnaire™ (RiiQ™), and EQ-5D-5L. Data were summarized descriptively, stratified by pathogen and baseline and hospitalization characteristics. Domain (general, upper respiratory, and lower respiratory) and sign/symptom subscores are presented for CSS; sign/symptom subscores are presented for RiiQ™ results.

resultsData from 635 patients with influenza, 248 with RSV, and 107 with hMPV were included. At enrollment, total CSS and general and lower respiratory signs/symptoms (LRS) scores were higher for RSV and hMPV than influenza. Between-pathogen differences were greatest for LRS scores. Dyspnea, rales/rhonchi, wheezing, and shortness of breath scores trended higher for RSV and hMPV than influenza. RiiQ™ scores for cough, fatigue, and short of breath were strongly correlated with corresponding clinician-rated symptoms.

conclusionsThese findings support the use of PROs (e.g., the RiiQ™) correlating with clinician assessments to gauge patient well-being and aid patient management by accurately assessing respiratory illness severity due to RSV, hMPV, or influenza.

Indexed as

HospitalizationInfluenza, HumanMetapneumovirusParamyxoviridae InfectionsRespiratory Syncytial Virus InfectionsRespiratory Tract InfectionsSeverity of Illness IndexAdolescentAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedRespiratory Syncytial Virus, HumanHARTIhMPVhospitalizationhuman metapneumovirusinfluenzapatient‐reported outcomesrespiratory syncytial virusRSV

Identifiers

PMID38692663
PMCPMC11062776
OpenAlexW4396589792

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.